Recce Pharmaceuticals Secures Hong Kong Patent for Anti-Infectives Until 2041
Recce Pharmaceuticals secures Hong Kong patent protection for Family 4 anti-infectives until 2041, marking sixth jurisdiction and strengthening Asia-Pacific IP strategy ahead of Phase 3 trials.
Key Takeaways
- Hong Kong patent extends Recce's IP protection to 2041 across six Asia-Pacific jurisdictions
- Coverage includes manufacturing processes and therapeutic applications for both R327 and R529 compounds
- Strategic positioning in US$2.5 billion Hong Kong market creates gateway for broader ASEAN expansion
- Patent timing strengthens partnership negotiation leverage ahead of Phase 3 Indonesia trial outcomes
- Broad administration route coverage enables diverse commercialisation pathways from hospital to outpatient settings
This is a special feature video produced for our partner.
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time